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: Hazard ratio (95%CI) for ischemic heart disease during 6 months follow-up in users of varenicline vs. NRT, adjusted for an unmeasured binary confounder with a hazard ratio of 3
This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. Biometrics 1998, 54(3) This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. Biometrics 1998, 54(3) This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT Rx (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. Biometrics 1998, 54(3) , 948-963 (equation 2.9). Table E7 : Hazard ratio (95%CI) for self-harm during 6 months follow-up in users of varenicline vs. NRT, adjusted for an unmeasured binary confounder with a hazard ratio of 3 This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. 
Table E11: Hazard ratio (95%CI) for cerebral infarction during 3 months follow-up in users of varenicline vs. NRT, adjusted for an unmeasured binary confounder with a hazard ratio of 3
This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. Biometrics 1998, 54(3) This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. Biometrics 1998, 54(3), 948-963 (equation 2.9 ). This tables shows how the observed hazard ratio (diagonal line of cells filled with light blue) would change in the presence of an unmeasured confounder with a hazard ratio of 3 and different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with red mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. In addition, the cells filled with dark red mark the situations in which this hazard would also be clinically meaningful according to our study protocol (HR>=1.5). These calculations are based on: Lin et al. Biometrics 1998, 54(3) , 948-963 (equation 2.9). 
